glp 1 for metabolic syndrome Why are GLP-1 agonists being used to treat patients with nonalcoholic fatty liver disease? What I love about GLP-1s

These include: Nausea, vomiting, and diarrhoea (very common, especially during dose escalation) Reduced appetite and abdominal discomfort Constipation Risk of hypoglycaemia when used with insulin or sulphonylureas Pancreatitis and gallbladder disease have been reported Thyroid C-cell tumours have been observed in animal studies, though the relevance to humans is unknown Important safety considerations when using both treatments include: Mounjaro can reduce the effectiveness of oral contraceptives due to delayed gastric emptying

GLP-1 receptor agonists slow down gastric emptying, which can reduce how much digoxin is absorbed into the bloodstream

Roberts P, Der C

But for those hesitant to go under the knife, GLP-1 therapy can be a bridge, helping them reach a safer BMI bracket and giving surgeons a better starting point for a successful operation

3 AZD5004 oral GLP-1R agonist Completed Ph